# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Baird analyst Colleen Kusy maintains Ocular Therapeutix (NASDAQ:OCUL) with a Outperform and lowers the price target from $18...
HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $14 price target.
Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company")))), a biopharmaceutical company committed to en...
Piper Sandler analyst Biren Amin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and maintains $15 price target.